Shopping Cart
Remove All
Your shopping cart is currently empty
Petosemtamab
😃Good
Catalog No. T76890Cas No. 2213450-26-9
Alias MCLA 158
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).
Petosemtamab
Petosemtamab
😃Good
Catalog No. T76890Alias MCLA 158Cas No. 2213450-26-9
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $355 | In Stock | In Stock | |
| 5 mg | $928 | In Stock | In Stock | |
| 10 mg | $1,490 | Inquiry | Inquiry |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:> 95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC). |
| Targets&IC50 | EGFR:0.22 nM (Kd), LGR5:0.85 nM (Kd) |
| In vitro | Treatment with MCLA-158(Petosemtamab) (1 µg/mL; 24 or 72 hours) induces the degradation of EGFR in EGFR+/LGR5+ colorectal cancer organoids[2]. |
| In vivo | Treatment with MCLA-158(Petosemtamab) (25 mg/kg/week, intravenous injection, for 6 weeks) leads to tumor regression in esophageal squamous cell carcinoma, gastric adenocarcinoma, and head and neck PDX models[2]. |
| Synonyms | MCLA 158 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | LGR5 & EGFR |
| Molecular Weight | 145.97 kDa |
| Cas No. | 2213450-26-9 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Petosemtamab | purchase Petosemtamab | Petosemtamab cost | order Petosemtamab | Petosemtamab in vivo | Petosemtamab in vitro | Petosemtamab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.